XNAS · ARVN
-0.23% · -$0.0200 · Vol 456.3K
After hours · updated 16:04:28 ET
Arvinas, Inc

Arvinas, Inc

PHARMACEUTICAL PREPARATIONS
$8.54
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is ARVN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Arvinas, Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2018
Employees
246
Country
US

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$8.50
Day high
$8.62
Day low
$8.34
Previous close
$8.56
52W high
$8.63
-1.10% from high
52W low
$6.98
94% of range
Market cap
$552.3M
EPS
$-1.0800
Shares out
64.5M
Volume
456.3K
VWAP
$8.50
Price history computed in-house
1W
+1.79%
1M
+22.35%
SMA 50 $7.97 · above
SMA 200 $7.97 · above
52W position 94%
Veridion warehouse edge

Warehouse intelligence for ARVN.

Veridion Score
40
0: 871: 392: 353: 104: 705: 60
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

ARVN insider activity

Arvinas, Inc

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for ARVN.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

ARVN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ARVN in this window.
Lobbying spend

ARVN lobbying filings, year to date.

Registered lobbying filings matched to Arvinas, Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ARVN in this window.
Latest news · ARVN
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for ARVN.
Options
Sovereign unlock shows live options positioning for ARVN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.